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ABSTRACT
Introduction: Local anesthetic infusion
techniques have been reported to reduce
opiate requirements and pain scores following
different kinds of surgery, including orthopedic
surgery, inguinal hernia, and Cesarean surgery
in women.
Methods: PRF-108 and PRF-110 formulations
were applied to the wound space in an
incisional model in pigs to test the hypothesis
that these formulations have better and longer
analgesic effects than the commercially
available ropivacaine solution (Naropin,
AstraZeneca).
Results: The data show significantly better
analgesic activity with PRF-108 and PRF-110
compared to ropivacaine. The duration of the
analgesic efficacy of PRF-108 and PRF-110 was at
least five times longer than that was measured
following treatment with ropivacaine. The data
further suggest that active clearance from the
injection site (the wound) is much slower for
PRF-108 and PRF-110 than for the commercial
ropivacaine solution.
Conclusion: Assessing the local concentration
of PRF compounds and commercially available
ropivacaine solution suggests that active
clearance from the injection site (the wound)
is much slower for PRF-108 and PRF-110 than
for ropivacaine.
Funding: PainReform.
Keywords: Incision; Pain; Pig; PRF-108;
PRF-110; Ropivacain; Surgery
Electronic supplementary material The online
version of this article (doi:10.1007/s40122-015-0043-9)
contains supplementary material, which is available to
authorized users.
D. Castel
The Neufeld Cardiac Research Institute and
Department of Physiology and Pharmacology,
Sackler School of Medicine, Tel-Aviv University,
Tel-Aviv, Israel
M. Naveh  A. Aharon
PainReform, c/o Medica VP, Herzeliya, Israel
O. Doron
Lahav Research Institute, Kibutz Lahav, Negev,
Israel
S. Meilin (&)
Neurology Division, MD Biosciences, Ness Ziona,
Israel
e-mail: sigal@mdbiosciences.com
Pain Ther (2016) 5:29–42
DOI 10.1007/s40122-015-0043-9
INTRODUCTION
Local anesthetic infusion techniques have been
reported to reduce opiate requirements and
pain scores following different kinds of
surgery, including orthopedic surgery [1, 2],
inguinal hernia [3], and Cesarean surgery in
women [4]. Decades ago, wound infiltration
with either ropivacaine or bupivacaine was
reported as a good pain control approach
following surgery [5]. In the present study, we
assessed the hypothesis that PRF-108 and
PRF-110 formulations afford prolonged pain
relief following surgery.
PRF-108 and PRF-110 are new
extended-release oily formulations of
ropivacaine and are generally recognized as
safe excipients intended for local
administration into surgical wounds. The
formulations are designed to slowly release the
ropivacaine. It is expected that the provision of
local analgesia over a long time span will reduce
the need for systemic analgesics, especially
opiates, and that this may also shorten the
hospitalization time. The two formulations are
very similar and differ in only a single
ingredient, DMPG
(1,2-dimyristoyl-sn-glycero-3 phosphoglycerol
NH4/Na salt). To test this hypothesis, the
above formulations were applied to the wound
space in an incisional model in pigs [6].
METHODS
Drugs
PRF-108 at a concentration of 4% ropivacaine in
either 4% ethanol (Group 3) or 6% ethanol
(Group 4) or PRF-110 in 6% ethanol was
injected sub-cutaneously in the incision area
at a volume of 2.5 mL on each side. The
ropivacaine hydrochloride solution (Naropin
1%, AstraZeneca) was diluted in saline to
achieve a concentration of 0.5%.
Vehicle-treated animals were treated with 6%
ethanol/viscous material.
Drug Formulation
All drug combinations were prepared by Nextar
ChemPharma Ltd., Israel, from the following
components: ropivacaine hydrochloride H2O
(Haorui Pharma-Chem. Inc.), lecithin
phospholipon 90G (PL90G; Phospholipid
GmbH), castor oil (Spectrum Chemical Mfg.
Corp.), cysteine hydrochloride (Spectrum
Chemical Mfg. Corp.), absolute ethanol
(Merck), and, for PRF-108 only, DMPG
(1,2-dimyristoyl-sn-glycero-3 phosphoglycerol
NH4/Na salt; Avanti). All components met the
‘generally recognized as safe’ criteria of the Food
and Drug Administration.
The composition of 4% ropivacaine
PRF-108 was ropivacaine hydrochloride
monohydrate 4.78% (w/w), PL90G 50.89% or
48.89% (w/w; 4% or 6% ethanol formulation,
respectively), castor oil 35.21% (w/w), cysteine
hydrochloride 0.10% (w/w), and ethanol 4%
or 6% (w/w). The composition of 4%
ropivacaine PRF-110 was ropivacaine HCl
monohydrate 4.78% (w/w), PL90G 53.91%
(w/w), castor oil 35.21% (w/w), cysteine HCl
0.10% (w/w) and ethanol 6.0% (w/w).
Ingredients were weighed and dissolved in
excess ethanol, blended by sonication in a
pharmaceutical reactor at 50 C. Sonication
was continued for 4 h, and additional 1-h
periods if needed, until a clear solution was
obtained. The solution was dried in a rotary
evaporator (rotor 60 rpm, vacuum
40–200 mbar) and the final alcohol content
was corrected to 4% or 6% as indicated.
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Animals and Housing
Danish Landrace X large white crossbred
weaned male pigs (n = 46) from the domestic
herd at Lahav Labs (Negev, Israel) were used.
Prior to the beginning of the experiment, all
animals were kept under conventional pig
production conditions. All pigs were 7–8 weeks
old and weighed 10 ± 1 kg at the start of the
study. The animals were housed in open pens
(1.4 9 2.4 m) 7 days prior to study initiation.
The pigs were kept in groups of two or three
during the acclimatization period and
throughout the experiment. Feeding occurred
three times daily using special pig food (Dry
Sows; Ct # 5420; Milobar, 7880, Oshrat, Israel),
and the pigs were provided opportunities to
root and chew for enrichment. Fresh water was
provided ad libitum by an automated system.
The pigs were kept on a 12-h light/dark cycle.
The study was approved by the Institutional
Animal Care and Use Committee (IACUC) and
adhered to guidelines of the Committee for
Research and Ethical Issues of the International
Association for the Study of Pain (IASP) [7]. All
tests were performed blind, that is, the
technician was unaware of the individual
animal’s treatment.
Habituation Protocol
The pigs were habituated to the protocol for
5 days prior to surgery. The researchers, the
veterinarian, and the animal care technicians
played with the pigs in their home pen for at
least 15 min, twice a day, on each day of the
acclimatization period and throughout the
experiment. As a result, the pigs became
familiar with their observers. This ensured
calm and consistent handling of the animals.
The same technicians cared for the animals
throughout the entire study period. No other
people were allowed into the housing facility.
To familiarize the pigs with the protocol and
technicians, they were trained to walk to the
preparation room daily during the habituation
period. The pigs were always returned to their
original pens with their original pen mates. The
habituation process was intended to reduce the
stress level of the pigs.
Anesthesia, Surgery, and Drug Application
On the day of surgery, the pigs walked freely to
the preparation room. The technicians carried
each animal in their hands and placed an
anesthetic facemask (Stephan Akzent Color)
on the pig’s mouth and nose. Each animal was
anesthetized with a 3% isoflurane/100% oxygen
mixture. The technician held the pig until it
was relaxed and sleepy. Then, the technician
placed the pig in a sternal position, still
connected to the anesthesia mask. The pig was
shaved and swabbed with 70% ethanol and
then carried to the operating room. The pig was
placed on the operating table and a sterile
environment was maintained. The area of the
incision was swabbed with antiseptic liquid
polidine solution (Polysept solution, Rekah
Pharmaceutical Industry Ltd.) and the
non-operated areas were covered with sterile
sheets. Blood oxygen saturation was monitored
throughout the anesthesia (Spacelab Medical).
The operation is fully detailed in Castel et al.
[6]. Briefly, a 6- to 7-cm incision was made
through only the skin and fascia, keeping the
muscle intact. The incision was made on the left
side of the lower back toward the caudal end.
Immediately after the incision was made, the
drug was applied to the pocket resulting from
the skin incision. Following drug
administration, the incisions were closed using
3–0 silk sutures (Assut UK Ltd.) and a
continuous suturing technique. Following the
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incision, all pigs received the antibiotic
marbofloxacin (10% w/v; Marbocyl,
Ve´toquinol UK Ltd.) at a total dose of 0.5 mL
per pig, which was administered into the neck
muscle via intramuscular injection. Each
animal was kept under anesthesia for the
duration of the surgery. The entire procedure,
from the time that the animal was introduced
to the facemask until the facemask was
removed, was performed in approximately
20 min. The animals were then returned to
their home pen for recovery.
Assessment of Mechanical Sensitivity
Mechanical sensitivitywas assessedusingvonFrey
filaments [Touch Test (von Frey) Sensory
Evaluator Kit, model 58011, Stoelting Co.]. The
tests were performed in the pig’s home pen. Von
Frey filaments ranging from a minimum of 1 g
(diameter= 0.229 mm; force= 9.804 mN) to a
maximum of 60 g (diameter = 0.711 mm;
force= 588.253 mN) were used. The intact side
(contralateral to the side of incision) was
introduced first to the von Frey filaments as a
control. The filaments were then applied
approximately 0.5 cm proximal to the incision
on the skin [6]. Each filament was applied three
times with a 5- to 10-s interval between
applications. If withdrawal was not achieved, a
thicker filament was applied. If withdrawal was
achieved, a thinner filament was applied. By
alternating the filaments, the force required to
achieve a withdrawal reaction was determined.
This procedure was carried out at different
time-pointsduring48 hof post-surgery follow-up.
Incision Healing
The incisions of all animals were scored
throughout the study period (48 h). Three
additional sham-operated animals and three
animals treated with PRF using the 6% ethanol
formulation were culled 14 days
post-administration and the area of the
incision was taken for further histology
analysis. The incision of these animals was
closely observed and scored during these
14 days of follow-up. The score was composed
of two categories: redness (0 = normal;
1 = slight redness at the area of the incision;
2 = diffuse redness) and swelling (0 = no
swelling; 1 = slight swelling; 2 = pronounced
swelling). The final score of each animal was
the sum of the scores on each category. The
incision area was photographed daily.
At the end of the study, photographs were
taken again, the animals were euthanized, and
the incision and surrounding areas were taken
for histological analysis of wound healing. The
skin samples were collected from each wound
area such that the surgical incision was located
in their center. The samples all had similar
dimensions (ca. 5 cm long 9 3 cm wide 9 2 cm
deep) and were individually identified. Their
cranial edge was marked with a tissue dye
(Davidson Marking System). The samples were
then pinned to a flat piece of polystyrene foam
to maintain their flat shape and were placed
individually into containers with 10% neutral
buffered formalin for fixation. The cranial edge
was also marked on the polystyrene foam. Each
sample was evaluated in three 5-lm
paraffin-embedded sections. Sample A was
approximately 1 cm from the marked
(proximal) edge, sample B was from the
middle, and sample C was approximately 1 cm
from the contralateral distal edge. The healing
of each section of the samples was graded. These
healing scores served to determine a grade for
the entire sample. The grading was as follows:
excellent (4) = full healing via a narrow fibrous
scar without significant inflammation; very
good (3) = full healing, similar to the above
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but with some less desirable variations, e.g.,
wider scar but still discrete and/or mild
inflammation; good (2) = full healing with
extensive local fibrosis, in some cases with
some mononuclear inflammation; and poor
(1) = all other types of tissue reactions.
Blood and Wound Liquid Collection
Venous blood samples (3.5 mL samples) for
measurement of the plasma concentration of
ropivacaine were drawn at 13 time-points over a
period of 38-h post-test item administration.
Blood samples were drawn into cooled test
tubes (at approximately 4 C) pre-loaded with
EDTA-K3. Samples were centrifuged within
15 min of sampling in a cooled centrifuge (at
approximately 4 C). The supernatant (plasma)
was collected for further analysis.
At 48 h, the animals were culled and the
wounds were opened. The wound liquid was
collected using a 10G needle and a pre-EDTA-K3
loaded syringe. The liquid was then centrifuged
and kept at -80 C until further analysis.
Analysis of Ropivacaine in PRF-108
and PRF-110 Plasma Samples
Quantitative analysis of ropivacaine levels in
plasma was performed using a HPLC/MS/MS
method on a Phenomenex Synergi column
150 9 2 mm, 4 lm, Polar-RP, 80A, P.N.
00F-4336-B0, flow rate 0.35 mL/min, at
40 ± 4 C, run time 4 min, mobile phase
acetonitrile/2.5 mM ammonium acetate/formic
acid, 40/60/0.2 v/v/v. Samples were diluted in
pig plasma and run against a standard
ropivacaine in pig plasma curve.
Study Design
Animals were assigned to five groups as follows:
vehicle-treated animals (Group 1);
Naropin-treated group (Group 2); PRF-108 in
4% ethanol (Group 3); PRF-108 in 6% ethanol
(Group 4); and PRF-110 in 6% ethanol
(Group 5). There were 4–6 animals per group.
The study was performed in four parts: part 1,
habituation (study day -5 until study day 0);
part 2, surgery and drug application; part 3,
pain assessment for 48 h; and part 4, blood
collection and tissue wound liquid collection
(Fig. 1).
Two additional sham-operated animals and
four additional animals were dosed with
PRF-108 using the 6% ethanol formulation.
These animals were followed for 14 days
post-injection. At day 14, the animals were
culled and the incision area was taken for
further histology analysis of wound healing.
Fig. 1 Study design. The ﬁgure shows the study activity
over a period of 48 h. However, six additional animals were
observed for a period of 14 days at day 14. These animals
were culled and the incision area was removed for wound
healing analysis
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Data Analysis
The results are presented as mean ± standard
error of the mean. Comparisons between groups
were performed using one-way analysis of
variance followed by Dunnett’s test (GraphPad
Prism, GraphPad Software, Inc.) and assuming
a normal distribution of data. Pharmacokinetic
data were analyzed using the Wilcoxon
non-parametric test. A P value \0.05 was
considered significant.
RESULTS
Assessment of pain for a period of 48 h
post-surgery and placebo application showed a
significant decrease in withdrawal force. At
baseline, the withdrawal force of the animals
was 60.00 ± 0.00 g. One hour post-dosing, the
mean group withdrawal force was as low as
2.80 ± 1.00 g at 3 h post-surgery for the
placebo-treated animals (P\0.05 vs. baseline).
This low withdrawal force was also detected on
study day 33 (1.67 ± 0.30 g). Treatment with
PRF-108 using a formulation of 4% ropivacaine/
6% ethanol or 4% ropivacaine/4% ethanol was
effective in increasing the withdrawal force at
3 h (35.50 ± 7.7 and 35.50 ± 7.9 g, respectively,
P\0.05 vs. the saline group). Treatment with
PRF-110 was as effective as PRF-108 with a
formulation of 4% ropivacaine/6% ethanol
(Fig. 2). At 24 h post-surgery, animals treated
with 4% ropivacaine/4% ethanol experienced
reduction in withdrawal force compared to
animals treated with 4% ropivacaine/6%
ethanol. However, this change was not
significant (16.33 ± 3.8 vs. 35.50 ± 7.9 g,
respectively). The mean group withdrawal
force for the animals treated with PRF-110 was
34.67 ± 8.4 g at 24 h post-surgery.
Naropin treatment was not as effective as
PRF-108 or PRF-110 in increasing the
withdrawal force. At 3 h post-application,
treatment with Naropin resulted in a mean
Fig. 2 The effect of PRF-108, PRF-110, and Naropin on withdrawal force following von Frey testing. *P\0.05 vs.
sham-operated animals. EtOH ethanol, Ropi ropivacaine
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group withdrawal force of 23.50 ± 7.6 g. At 8 h
post-Naropin application, there was no
significant difference between the withdrawal
force of the saline-treated group and the
Naropin-treated group. In comparison, the
duration of analgesia following treatment with
PRF-108 or PRF-110 was 30–33 h (Fig. 3).
A pharmacokinetic study exploring the level
of ropivacaine in the plasma following
treatment with either PRF-108 or Naropin
suggested no difference in the maximum
plasma concentration (Cmax) between PRF-108
and Naropin (2919 vs. 3162 ng/mL,
respectively; Fig. 4). A P value of 0.0520 was
found when comparing the time at which Cmax
was observed (Tmax) for PRF-108 and Naropin
(6.50 vs. 0.5 h, respectively; Table 1).
Forty-eight hours post-dosing, analysis of the
blood ropivacaine concentration showed a very
low level of ropivacaine following treatment
with PRF-108, PRF-110, or Naropin. No
difference was found between the levels of
ropivacaine in the animals treated with
PRF-108 using 6% ethanol versus the 4%
ethanol formulation (102 ± 34 vs. 70 ± 20 ng/
mL). No difference was found between PRF-110
and PRF-108 using the 6% ethanol formulation
(31 ± 5 vs. 102 ± 34 ng/mL). The area under the
curve of the plasma concentration of
ropivacaine demonstrated a significant
increase following PRF-108 (44,579 ± 3662)
versus Naropin (5918 ± 1008; P\0.05)
administration (Table 1). Analysis of the
wound fluid revealed no significant difference
in the ropivacaine concentration between the
following treatment groups: PRF-108 4%
ropivacaine/4% ethanol, PRF-108 4%
ropivacaine/6% ethanol, and PRF-110. A
comparison of the wound concentration of
ropivacaine in the PRF-treated and the
Naropin-treated groups showed a significantly
higher concentration in animals treated with
Fig. 3 The effect of PRF-108, PRF-110 and Naropin on
the duration of analgesia. PRF-108 and PRF-110 showed a
signiﬁcantly lower analgesia period, exceeding 24 h, vs.
Naropin. *P\0.05 vs. sham-operated animals. EtOH
ethanol, Ropi ropivacaine
Pain Ther (2016) 5:29–42 35
4% ropivacaine/6% ethanol and PRF-110
(7777 ± 2822 and 3799 ± 599 ng/mL,
respectively, vs. 15 ± 13 ng/mL, P\0.05;
Fig. 5b). However, the ratio of the ropivacaine
concentration in the wound fluid versus the
ropivacaine blood concentration at 48 h
post-dosing was higher after treatment with
PRF-110 or PRF-108 than following treatment
with Naropin (Fig. 5c).
No abnormalities were noticed during the
48-h observation of the incision in any of the
treatment groups during the 14 days of wound
observation. No swelling or redness was noted.
At 14 days post-dosing, the wounds of four
additional animals treated with PRF-108 in 6%
ethanol formulation and two sham-operated
animals were harvested. Gross observation of
the incisions suggests a clean and almost full
incision bridge with no difference between the
sham-operated animals and the PRF-108 in 6%
ethanol-dosed animals (Fig. 6). Table 2 details
the histological findings. The total histology
score of the PRF-108 in 6% ethanol group
ranged between 2 and 4. In comparison, the
total scores of the sham-operated animals
ranged between 2 and 3. Overall, the histology
analysis suggests that treatment with PRF-108 in
6% ethanol did not affect the healing process.
DISCUSSION
The current study was designed to investigate
the activity of local treatment with PRF-108 or
PRF-110 using the post-operative pain model in
pigs. The activity of these formulations was
compared to the commercially available
ropivacaine solution, Naropin. An additional
aim was to assess the significance of differences
in the ethanol content in the final formulation
on its efficacy and pharmacokinetics. All
formulations in this study contained 4%
ropivacaine. The data show: (1) a significantly
better analgesic effect of PRF-108 and PRF-110
vs. Naropin. (2) The duration of analgesia of
PRF-108 and PRF-110 was significantly longer
than that of Naropin. (3) A significantly longer
Tmax of PRF-108 vs. Naropin. (4) At 48 h
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Fig. 4 Changes in ropivacaine plasma levels over time following PRF-108 or Naropin dosing
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ropivacaine was a hundred times higher
following treatment with PRF-108 or PRF-110
vs. treatment with ropivacaine. (5) No
difference was found between PRF-108 in 4%
ethanol formulation vs. PRF-108 using 6%
ethanol.
There is extensive evidence suggesting that
pigs’ skin resembles the human skin in
structure, function [8, 9], innervation [10] and
response to mechanical and thermal
stimulation [6, 11–13]. Additionally, pigs have
become a standard wound healing model due to
the similarities to humans, including
re-epithelialization rather than contraction
[14]. Indeed, the level and duration of the
effect of a single dose of Naropin are in line
with what was found in humans. A
double-blind randomized trial of wound
infiltration with ropivacaine after breast cancer
surgery with axillary node dissection suggests
significant pain relief for 6 h post-treatment
[15]. Pharmacokinetic studies in humans
following spinal ropivacaine administration
show a plasma peak at 0.5 h
Table 1 Pharmacokinetic data of Naropin and PRF-108
Cmax (ng/mL) Tmax (h) AUClast AUCinf T1/2 (h)
Naropin 0.5%
N 4 4 4 4 4
Mean 2314.25 0.50 5917.69 5939.67 2.69
SD 739.67 0.00 2016.35 2030.44 0.22
Median 2283.00 0.50 5879.13 5898.40 2.68
Min 1530.00 0.50 3574.75 3581.98 2.49
Max 3161.00 0.50 8337.75 8379.89 2.92
Lower 95% CI 1137.28 2709.23 2708.79 2.34
Upper 95% CI 3491.22 9126.14 9170.55 3.05
PRF-108
N 4 4 4 4 4
Mean 2318.50 6.50 44,578.81 47,182.33 10.93
SD 457.05 6.35 7323.90 7349.25 2.47
Median 2262.00 6.50 45,325.88 47,750.04 10.93
Min 1831.00 1.00 36,054.00 38,571.23 8.13
Max 2919.00 12.00 51,609.50 54,658.00 13.74
Lower 95% CI 1591.23 -3.61 32,924.85 35,488.02 7.00
Upper 95% CI 3045.77 16.61 56,232.77 58,876.63 14.87
P value NS 0.0520 0.0671 0.0671 0.0671
AUCinf area under curve extrapolated to inﬁnity from dosing time, based on the last observed concentration, AUClast area
under curve last: from dosing to last measurable concentration, CI conﬁdence interval, Cmax maximum plasma
concentration, NS not signiﬁcant, SD standard deviation, T1/2 half-life, Tmax time at which Cmax was observed
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post-administration and at 4 h
post-administration the level of ropivacaine in
the plasma was greatly reduced [16]. This is in
line with the data described in this work.
Continuous wound infusion of ropivacaine
results in a longer presence of ropivacaine in
the blood that is dependent on the duration of
the infusion. The advantage of a local infusion
is the relatively low systemic exposure [17]. A
recent comparison between the post-operative
analgesia using local anesthetics such as
ropivacaine or bupivacaine following a
continuous wound infusion approach with
traditional patient-controlled analgesia (PCA)
suggests that continuous wound infusion is as
effective for post-operative analgesia as
traditional PCA. Furthermore, this therapy
reduced the incidences of drowsiness,
dizziness, respiratory depression and decreased
the intensive care unit stay and hospital
expenditure [18, 19]. These studies emphasize
the importance of prolonged ropivacaine
activity immediately post-surgery. A study
with a patient who underwent posterior
lumber instrumented fusion for degenerative
disc disease suggests that routine use of epidural
infusion anesthesia for lumbar spine surgery has
too many risks and offers very little advantages
over PCA [20]. Gulle et al. [21] also showed that
a combination of epidural ropivacaine and oral
oxycodone can reduce the pruritus which is
often reported following epidural analgesia with
bupivacaine, epinephrine and fentanyl after
lumbar fusion surgery. In knee arthroplasty
Fig. 5 Concentration of ropivacaine in the plasma (A) and the wound (B) 48 h post-treatment with PRF-108/4% ethanol,
PRF-108/6% ethanol, PRF-110 or Naropin. *P\0.05 vs. the Naropin-treated group. EtOH ethanol, Ropi ropivacaine
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surgery, local injection of analgesics
periarticularly at the end of the operation and
intraarticularly at 21 h post-operatively
provided excellent pain relief and earlier home
discharge. In addition, the authors reported a
high degree of patient satisfaction after
6 months [2]. The current study shows that a
single dose of PRF-108 or PRF-110, a
slow-release ropivacaine formulation, has a
prolonged analgesic effect which can be
detected for up to 30 h, without the need for
additional dosing. Local dosing of PRF-108 and
PRF-110 immediately before closure of the
surgery wound has the advantages of
prolonged ropivacaine activity and balancing
the infusion catheterization risk.
In this study, four additional animals were
operated and injected with PRF-108 using the
6% ethanol formulation. Ethanol is known to
interfere with wound healing. Most studies refer
to the effect of systemic exposure to ethanol as
an inhibition factor in wound healing. It is
suggested that early dermal inflammatory
responses, including MPO activity, production
of MIP-2, KC, and IL-1beta, are impaired in mice
given ethanol before injury, which may also
have detrimental effects on later stages of
wound healing [22]. We therefore observed
the incision healing process in the group that
was exposed to the formulation containing the
higher ethanol percentage. Our data suggest no
effect of this formulation on incision healing
and closure.
CONCLUSIONS
This study suggests that PRF-108 and PRF-110
clearance from the wound is slower than that of
the commercial ropivacaine solution. This can
explain thehigh efficacy andprolongedduration
of activity of these formulations compared to
Naropin. It also suggests that an ethanol
concentration of up to 6% does not affect the
efficacy or clearance. Gross observations and
detailed histology analysis suggest that the 6%
formulation had no detrimental effects on
incision healing. The low concentration of
ropivacaine found in the blood following
treatment with PRF-108 or PRF-110 suggests
that the source of the analgesic activity was due
to the high ropivacaine concentration found
locally in the wound fluid and was not due to
systemic exposure.
Fig. 6 Representative photographs of macroscopic obser-
vations. a A 7.5-cm-long sample from an animal treated
with 4% ropivacaine/6% ethanol (Group 3). The incision
is well apposed and visible up to a point. Sutures continue
for approximately 1.8 cm beyond the visible incision
(marked). Small dried scabs in suture holes and to a lesser
degree along the entire visible incision. No thickening is
noted. b A sample from an animal of the sham group
(Group 1) with an 8.4-cm-long incision. The incision is
well apposed and visible throughout, except in the 1 cm
away from the mark where it is barely perceptible
(marked). A slightly larger scab in approximately one-third
of the incision line and small dried scabs limited to suture
holes. No thickening is noted
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5 A FE with a pustule Excellent Excellent healing (4)
B FE Excellent
C FE with a pustule Excellent
6 A FE with a pustule A narrow discrete scar; in the deep




B FE with a pustule A narrow discrete scar; a large pustule
nearby probably at suture entry
(excellent)
C FE with a pustule A narrow discrete scar; a large pustule
nearby probably at suture entry
(excellent)
7 A – A scar is not identiﬁed, complete
healing
Very good healing (3)
B FE with pustule A narrow discrete scar; near it a
suture tract, below it a small focus
of granulomatous and lesser
neutrophilic inﬂammation with
some amphophilic material (good)
C HF with pustule A narrow scar; no inﬂammation
(excellent)
8 A HF with pustule A somewhat wide area of ﬁbrosis in
dermis and SC, suture cavity,
minimal inﬂammation (very good)
Good–very good
healing (2–3)
B HF with pustule Scar not clearly identiﬁed, an area of
ﬁbrosis in deep dermis with an
epidermal inclusion (from suture)
and mild inﬂammation (good–very
good)
C HF with pustule A somewhat wide area of ﬁbrosis in
dermis and SC, multifocal mild to
moderate mononuclear
inﬂammation in SC (good)
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9 A HF with pustule A narrow scar in deep dermis to HF,
mild ﬁbrosis in SC, a small suture
tract (excellent)
Good healing (2)a
B HF with pustule A narrow ﬁbrous scar immediately
next to a suture tract with many
neutrophils, suggestive of bacterial
infection (poor)
C FE, large pustules A discrete scar is not identiﬁed;
moderate ﬁbrosis without
inﬂammation (good)
10 A FE with pustule A somewhat wide scar without
inﬂammation (very good)
Very good healing (3)
B FE, large pustules Moderate ﬁbrosis in dermis and SC
with minimal inﬂammation, suture
tract (good)
C FE with pustule A narrow and discrete scar, next to it
a tract (excellent)
Each sample was evaluated in three sections: sample A is approximately 1 cm from the marked (proximal) edge; sample B is
from the middle; sample C is approximately 1 cm from the contralateral distal edge
FE fully epithelialized, HF hair follicle, SC subcutis/subcutaneous
a Neutrophilic inﬁltration suggestive of the presence of bacterial infection
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